{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T17:03:26Z","timestamp":1758992606094},"reference-count":33,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T00:00:00Z","timestamp":1092009600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2004,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Treatment with high doses (2\u20136\u00a0mg\u00a0day<jats:sup>\u22121<\/jats:sup>) of human growth hormone (hGH) in patients with human immunodeficiency virus (HIV)\u2010associated lipodystrophy syndrome (HALS) has been shown to increase concentrations of total insulin\u2010like growth\u2010factor\u2010I (IGF\u2010I) more than twofold greater than the normal upper range and is accompanied by adverse effects such as joint pain and glucose intolerance.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold> We performed a 16\u2010week open\u2010labelled prospective pilot study in six male HALS patients using a s.c. low\u2010dose hGH, 0\u00b77\u00a0mg\u00a0day<jats:sup>\u22121<\/jats:sup>, aiming to examine the impact on total and free IGF\u2010I and fat distribution. Glucose metabolism was examined by oral glucose tolerance tests and hyperinsulinaemic euglycaemic clamps.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Total IGF\u2010I increased twofold (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00\u00b701) and free IGF\u2010I increased 2\u00b75\u2010fold (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00\u00b701) to the level of the normal upper range. HDL\u2010cholesterol increased (<jats:italic>P\u00a0=<\/jats:italic>\u00a00\u00b701). Patients reported improvements of lipodystrophy, which was supported by a decreased waist\u2010to\u2010thigh ratio (<jats:italic>P\u00a0=<\/jats:italic>\u00a00\u00b701), and waist\u2010to\u2010hip ratio (<jats:italic>P\u00a0=<\/jats:italic>\u00a00\u00b706). Ratio of peripheral to trunk soft tissue mass increased (<jats:italic>P\u00a0=<\/jats:italic>\u00a00\u00b701, measured by dual\u2010energy X\u2010ray absorptiometry scans) and a trend towards reduction in percentage of trunk fat was suggested (<jats:italic>P\u00a0=<\/jats:italic>\u00a00\u00b712). Total fat mass, exercise capacity, glucose tolerance, glucose disposal rate and immune status, respectively, did not change (all <jats:italic>P<\/jats:italic>\u00a0&gt;\u00a00\u00b75). The patients did not complain of arthralgia or other known GH\u2010related side\u2010effects.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Sixteen weeks\u2019 treatment of lipodystrophic HIV\u2010infected patients with hGH, 0\u00b77\u00a0mg\u00a0day<jats:sup>\u22121<\/jats:sup>, increased total and free IGF\u2010I twofold and appeared safe and tolerable. The potential of low\u2010dose hGH in the treatment of HIV\u2010lipodystrophy awaits examination by placebo\u2010controlled, randomized trials.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2004.01380.x","type":"journal-article","created":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T16:17:13Z","timestamp":1092068233000},"page":"561-568","source":"Crossref","is-referenced-by-count":16,"title":["Low\u2010dose growth hormone and human immunodeficiency virus\u2010associated lipodystrophy syndrome: a pilot study"],"prefix":"10.1111","volume":"34","author":[{"given":"O.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. B.","family":"Haugaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Flyvbjerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U. B.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"\u00d8rskov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Madsbad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. O.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,8,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/317477"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00201-4"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12656-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200110190-00012"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021704"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200208010-00002"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200403010-00004"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.8.3480"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-4-199908170-00024"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.2.942"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/00002030-199910220-00013","article-title":"Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV","volume":"13","author":"Wanke C","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.8.1443"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.3.727"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04056-3"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8227(99)00008-X"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1979.237.3.E214"},{"key":"e_1_2_6_19_2","first-page":"169","article-title":"Non\u2010competitive time\u2010resolved immunofluorometric assays for determination of human insulin\u2010like growth factor I and II","volume":"5","author":"Frystyk J","year":"1995","journal-title":"Growth Regul"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(94)00602-4"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.8.3033"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.12.4251"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.8.2968"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-11-199612010-00002"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-11-199612010-00001"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.504"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30469-9"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1004910"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000184186"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.79.4.1070"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-1-207"},{"key":"e_1_2_6_32_2","first-page":"6","article-title":"Imitation of normal plasma growth hormone profile by subcutaneous administration of human growth hormone to growth hormone deficient children","volume":"102","author":"Christiansen JS","year":"1983","journal-title":"Acta Endocrinol (Copenh)"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.11.4028"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1123\/ijsnem.11.s1.s105","article-title":"Pathophysiology of body composition and metabolic abnormalities in HIV\u2010infection: therapeutic implications. Int","volume":"11","author":"Hellerstein MK","year":"2001","journal-title":"J Sport Nutr Exerc Metab"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2004.01380.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2004.01380.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T23:38:02Z","timestamp":1697240282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2004.01380.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["10.1111\/j.1365-2362.2004.01380.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2004.01380.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}